«We could apply the strategy used in this study to quickly identify and
design small molecule drugs for other RNA - associated diseases,» explained study first author Sai Velagapudi, a research associate in the Disney lab.
Not exact matches
In a novel animal study
design that mimicked human clinical trials, researchers at University of California, San Diego School of Medicine report that long - term treatment using a
small molecule drug that reduces activity of the brain's stress circuitry significantly reduces Alzheimer's disease (AD) neuropathology and prevents onset of cognitive impairment in a mouse model of the neurodegenerative condition.
Small molecule drugs can be screened or
designed to increase telomerase activity exclusively within stem cells for disease treatment as well as anti-aging therapies without increasing the risk of cancer.
«They also provide a promising strategy for identifying
small molecule drugs designed to treat Alzheimer's disease and other neurological disorders.»
Anderson and Valerie Grum - Tokars, a junior structural biologist on the team, developed a three - dimensional structure of human p38 MAPK, enabling the chemists to
design and synthesize novel
drug - like
small molecules that would disable it.
An emerging strategy in early
drug discovery entails using fragments, i.e.
molecules smaller than conventional
drug candidates, as starting points for
design of novel therapeutic compounds.
The Unit's scientific mission covers the
design, synthesis, molecular modeling, as well as biophysical, biochemical and cellular studies of
small -
molecule probes and
drug candidates targeting nucleic acids or proteins involved in cancer.
Other companies, including the Swiss
drug giants Novartis and Roche, along with Boston's Paratek Pharmaceuticals, are developing ingestible
small -
molecule drugs designed to increase the inclusion of SMN2 «s exon 7.
Further the Meiler laboratory develops a structure - based
drug design module for ROSETTA and docking protocols particularly suited for docking
small molecules into comparative models.
As reported online in PLoS One on October 3, Hopkins colorectal cancer specialists John Abraham, Ph.D., and Stephen Meltzer, M.D. - working with the notion that
small molecules generally make better treatment packages -
designed small bits of protein only 10 amino acids long as the foundation for their
drugs.
I am interested in Scientist position for
designing and developing novel
small molecules, developing new synthetic routes and process optimization, for
drug discovery and development.